Latest CHOP Stories
Younger lymphoma patients given a more intensive chemotherapy regimen combined with rituximab live much longer, and are more than twice as likely to remain in remission 4 years later, compared to patients given standard chemo.
Lymphoma is often difficult to treat in elderly patients because they cannot always tolerate chemotherapy.
SEATTLE, April 4, 2011 /PRNewswire/ -- Cell Therapeutics, Inc.
SEATTLE, March 21, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) today announced that it has initiated its randomized pivotal trial of pixantrone for the treatment of relapsed/refractory diffuse large B-cell lymphoma ("DLBCL").
ORLANDO, Fla., Dec. 5, 2010 /PRNewswire-USNewswire/ -- The next generation of drug therapies and enhanced treatment approaches for various forms of lymphoma are evolving as researchers continue to better understand how these cancers progress.
SEATTLE, May 18 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTA) reported today preliminary cardiac safety results from a North American randomized phase II trial which substituted pixantrone for doxorubicin in the standard CHOP-R regimen.
- A member of the swell-mob; a genteelly clad pickpocket. Sometimes mobsman.